REG - Oxford Cannabinoid - Notice of Results

Oxford Cannabinoid Technologies HoldingsAnnouncement

23/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240123:nRSW5175Aa&default-theme=true

RNS Number : 5175A  Oxford Cannabinoid Tech.Holdings  23 January 2024

 

Oxford Cannabinoid Technologies Holdings plc

("OCTP" or the "Company")

 

Notice of Results

&

Analyst and Investor Presentations

Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP), the biotech company
developing prescription cannabinoid medicines, intends to announce its results
for the six-month period ended 31 October 2023, on Tuesday 30 January 2024.

Analyst Briefing, 09:30, Tuesday 30 January 2024

A briefing for analysts will be held at 09:30 GMT on the day of the results.

Analysts interested in attending OCTP's briefing should contact Acuitas
Communications by emailing oct@acuitascomms.com or by calling 020 3745 0293.

Investor Presentation, 13:30, Tuesday 30 January 2024

A live online presentation to existing and prospective shareholders will take
place at 13:30 GMT on Tuesday 30 January 2024 via the Investor Meet Company
platform.

Questions may be submitted online pre-event via the 'Investor Meet Company'
dashboard up to 09:00 the day before the meeting or at any time during the
live presentation. Investors can sign up to Investor Meet Company for free and
add to meet Oxford Cannabinoid Technologies Holdings plc via:
https://www.investormeetcompany.com/oxford-cannabinoid-technologies-holdings-plc/register-investor

Investors who already follow OCTP on the Investor Meet Company platform will
automatically receive an invitation to the event.

The Directors of the Company accept responsibility for the content of this
announcement.

Enquiries:

 

 Oxford Cannabinoid Technologies Holdings plc  +44 (0)20 3034 2820
 Clarissa Sowemimo-Coker (CEO)                 clarissa@oxcantech.com

 Cairn Financial Advisers LLP
 Emily Staples                                 +44 (0)20 7213 0897
 Jo Turner                                     +44 (0) 20 7213 0885

 Axis Capital Markets Limited
 Richard Hutchison                             +44 (0)20 3026 0320

 Acuitas Communications                        020 3745 0293 / 07799 767676
 Simon Nayyar                                  simon.nayyar@acuitascomms.com
 Arthur Dingemans                              arthur.dingemans@acuitascomms.com

 

About Oxford Cannabinoid Technologies Holdings Plc:

Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the holding company
of Oxford Cannabinoid Technologies Ltd (together the "Group"), a
pharmaceutical Group developing prescription cannabinoid medicines initially
targeting the US$ multi-billion global pain market.

 

OCTP currently has a portfolio of four drug development programmes. Its lead
compound, OCT461201, will initially target neuropathic and visceral pain
(including irritable bowel syndrome ("IBS") and chemotherapy induced
peripheral neuropathy ("CIPN"). The global market for CIPN alone is currently
forecast to reach US$1.17bn by 2028.

 

OCTP's drug development pipeline comprises both natural and synthetic
compounds, and includes compounds targeting trigeminal neuralgia, a severe
type of face pain, and cannabinoid derivatives targeting pain and potentially
other therapeutic areas. Having established an exclusive licence agreement
with Canopy Growth Corporation for their entire pharmaceutical cannabinoid
derivative library, OCTP now has a portfolio of almost five hundred
derivatives and intellectual property rights including fourteen patent
families and associated research data.

 

OCTP has a clearly defined path to commercialisation, revenues and growth. The
Group is developing drug candidates through clinical trials to gain regulatory
approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe
them with confidence. OCTP's portfolio aims to balance risk, value and time to
market, whilst ensuring market exclusivity around all its key activities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORDLLFLZFLFBBZ